Quarterly ResultJun 15, 2026, 04:52 PM
Pharma-Bio Serv Q2 Net Income +144% to $232,986; EPS $0.010
AI Summary
Pharma-Bio Serv reported strong financial results for the second quarter and first half of fiscal year 2026. Net income for the three months ended April 30, 2026, surged by 144% to $232,986, with diluted EPS increasing to $0.010. Revenues also grew by 11.8% to $2.7 million, and the company moved from an operating loss to a profit. For the six-month period, net income rose by 155.9% to $265,846, and the company declared a cash dividend of $0.075 per common share.
Key Highlights
- Q2 2026 net income increased 144% to $232,986 from $95,353 in Q2 2025.
- Q2 2026 diluted EPS rose 150% to $0.010 from $0.004 in Q2 2025.
- Q2 2026 revenues grew 11.8% to $2,702,943 from $2,417,044 in Q2 2025.
- Six-month net income increased 155.9% to $265,846 from $103,889 in 2025.
- Six-month diluted EPS rose 140% to $0.012 from $0.005 in 2025.
- Cash dividend of $0.075 per common share was declared and paid in Q2 2026.
- Repurchased 4,300 shares for $2,390 under the stock repurchase program.
- Net cash provided by investing activities was $879,613 for six months, up from a use of $2.2M.
Price Impact
More from PBSV